The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19

被引：19
|
作者：
Gozzetti, Alessandro [1 ]
Capochiani, Enrico [2 ]
Bocchia, Monica [1 ]
机构：
[1] Univ Siena, Div Hematol, Siena, Italy
[2] Azienda USL Toscana NordOvest, Ctr Translat Med, Hematol Unit, Livorno, Italy
来源：
LEUKEMIA | 2020年 / 34卷 / 10期
关键词：
D O I：
10.1038/s41375-020-01038-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2815 / 2816
页数：2
相关论文
共 50 条
  • [21] Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study
    Alessandro M. Vannucchi
    Benedetta Sordi
    Alessandro Morettini
    Carlo Nozzoli
    Loredana Poggesi
    Filippo Pieralli
    Alessandro Bartoloni
    Alessandro Atanasio
    Filippo Miselli
    Chiara Paoli
    Giuseppe G. Loscocco
    Andrea Fanelli
    Ombretta Para
    Andrea Berni
    Irene Tassinari
    Lorenzo Zammarchi
    Laura Maggi
    Alessio Mazzoni
    Valentina Scotti
    Giorgia Falchetti
    Danilo Malandrino
    Fabio Luise
    Giovanni Millotti
    Sara Bencini
    Manuela Capone
    Marie Pierre Piccinni
    Francesco Annunziato
    Paola Guglielmelli
    Leukemia, 2021, 35 : 1121 - 1133
  • [22] Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study
    Vannucchi, Alessandro M.
    Sordi, Benedetta
    Morettini, Alessandro
    Nozzoli, Carlo
    Poggesi, Loredana
    Pieralli, Filippo
    Bartoloni, Alessandro
    Atanasio, Alessandro
    Miselli, Filippo
    Paoli, Chiara
    Loscocco, Giuseppe G.
    Fanelli, Andrea
    Para, Ombretta
    Berni, Andrea
    Tassinari, Irene
    Zammarchi, Lorenzo
    Maggi, Laura
    Mazzoni, Alessio
    Scotti, Valentina
    Falchetti, Giorgia
    Malandrino, Danilo
    Luise, Fabio
    Millotti, Giovanni
    Bencini, Sara
    Capone, Manuela
    Piccinni, Marie Pierre
    Annunziato, Francesco
    Guglielmelli, Paola
    LEUKEMIA, 2021, 35 (04) : 1121 - 1133
  • [23] Reply: Potential role of Janus kinase inhibitors in COVID-19
    Napolitano, Maddalena
    Fabbrocini, Gabriella
    Patruno, Cataldo
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (01) : E65 - E65
  • [24] A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia
    Yoshiya Tanaka
    Inflammation and Regeneration, 43
  • [25] A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia
    Tanaka, Yoshiya
    INFLAMMATION AND REGENERATION, 2023, 43 (01)
  • [26] Janus Kinase inhibitors for the treatment of hospitalized patients with COVID-19
    Florescu, Diana F.
    Kalil, Andre C.
    CURRENT OPINION IN CRITICAL CARE, 2021, 27 (05) : 493 - 496
  • [27] Ruxolitinib withdrawal due to the COVID-19
    Marko Lucijanic
    Rajko Kusec
    Leukemia, 2021, 35 : 1218 - 1218
  • [28] Ruxolitinib withdrawal due to the COVID-19
    Lucijanic, Marko
    Kusec, Rajko
    LEUKEMIA, 2021, 35 (04) : 1218 - 1218
  • [29] Aggressive Skin Cancers Occurring in Patients Treated With the Janus Kinase Inhibitor Ruxolitinib
    Blechman, Adam B.
    Cabell, Christine E.
    Weinberger, Christine H.
    Duckworth, Anna
    Leitenberger, Justin J.
    Zwald, Fiona O.
    Russell, Mark A.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2017, 16 (05) : 508 - 511
  • [30] Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis
    Miyawaki, Hiroshi
    Kioka, Hidetaka
    Sato, Kazuaki
    Kurashige, Masako
    Ozawa, Takayuki
    Shibayama, Hirohiko
    Hikoso, Shungo
    Morii, Eiichi
    Yamauchi-Takihara, Keiko
    Sakata, Yasushi
    INTERNAL MEDICINE, 2020, 59 (02) : 229 - 233
12345